Glenmark Pharma unveils lower cost alternative to Bumex Injection
Mumbai: Glenmark Pharmaceuticals Inc., USA has announced that the company has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials.The product is a generic version of Bumex Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC. Commenting on the launch, Vijay Raghavan, Senior Vice President, Business...
Mumbai: Glenmark Pharmaceuticals Inc., USA has announced that the company has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials.
The product is a generic version of Bumex Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.
Commenting on the launch, Vijay Raghavan, Senior Vice President, Business Development Portfolio, Product Launch & Strategy said, “We are very pleased to bring to market a lower cost alternative to Bumex Injection, 0.25 mg/mL. This launch of Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials affirms our commitment to Glenmark’s continued focus on institutional business.”
Read also: JB Pharma forays into Statin segment, acquires Razel franchise from Glenmark for Rs 314 crore
According to IQVIA sales data for the 12-month period ending November 2022, the Bumex Injection, 0.25 mg/mL market achieved annual sales of approximately $16.5 million*.
Glenmark’s current portfolio consists of 179 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA.
"In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio," Glanmark stated.
Read also: Glenmark Pharma unveils triple FDC Zita-PioMet for Type 2 diabetes in India
